Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Kira Pharmaceuticals","sponsor":"Quan Capital","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Kira Pharmaceuticals"}]

Kira Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases

Details:

Kira's most advanced program, P014, is a first-in-class biologic drug with a unique mechanism of action designed to inhibit both upstream and downstream complement targets.

Lead Product(s): P014

Therapeutic Area: Immunology Product Name: P014

Highest Development Status: Discovery Platform Product Type: Large molecule

Partner/Sponsor/Collaborator: Quan Capital

Deal Size: $46.0 million Upfront Cash: Undisclosed

Deal Type: Financing November 12, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY